PortalPublikationenSurvival outcomes and clinical benefit in patients with acut...

Survival outcomes and clinical benefit in patients with acute myeloid leukemia treated with glasdegib and low-dose cytarabine according to response to therapy

Standard

Survival outcomes and clinical benefit in patients with acute myeloid leukemia treated with glasdegib and low-dose cytarabine according to response to therapy. / Cortes, Jorge E; Heidel, Florian H; Fiedler, Walter; Smith, B Douglas; Robak, Tadeusz; Montesinos, Pau; Candoni, Anna; Leber, Brian; Sekeres, Mikkael A; Pollyea, Daniel A; Ferdinand, Roxanne; Ma, Weidong Wendy; O'Brien, Thomas; O'Connell, Ashleigh; Chan, Geoffrey; Heuser, Michael.

in: J HEMATOL ONCOL, Jahrgang 13, Nr. 1, 14.07.2020, S. 92.

Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung

Harvard

Cortes, JE, Heidel, FH, Fiedler, W, Smith, BD, Robak, T, Montesinos, P, Candoni, A, Leber, B, Sekeres, MA, Pollyea, DA, Ferdinand, R, Ma, WW, O'Brien, T, O'Connell, A, Chan, G & Heuser, M 2020, 'Survival outcomes and clinical benefit in patients with acute myeloid leukemia treated with glasdegib and low-dose cytarabine according to response to therapy', J HEMATOL ONCOL, Jg. 13, Nr. 1, S. 92. https://doi.org/10.1186/s13045-020-00929-8

APA

Cortes, J. E., Heidel, F. H., Fiedler, W., Smith, B. D., Robak, T., Montesinos, P., Candoni, A., Leber, B., Sekeres, M. A., Pollyea, D. A., Ferdinand, R., Ma, W. W., O'Brien, T., O'Connell, A., Chan, G., & Heuser, M. (2020). Survival outcomes and clinical benefit in patients with acute myeloid leukemia treated with glasdegib and low-dose cytarabine according to response to therapy. J HEMATOL ONCOL, 13(1), 92. https://doi.org/10.1186/s13045-020-00929-8

Vancouver

Cortes JE, Heidel FH, Fiedler W, Smith BD, Robak T, Montesinos P et al. Survival outcomes and clinical benefit in patients with acute myeloid leukemia treated with glasdegib and low-dose cytarabine according to response to therapy. J HEMATOL ONCOL. 2020 Jul 14;13(1):92. https://doi.org/10.1186/s13045-020-00929-8

Bibtex

@article{76542e693c984dd6a8ca68c6f49e28db,
title = "Survival outcomes and clinical benefit in patients with acute myeloid leukemia treated with glasdegib and low-dose cytarabine according to response to therapy",
abstract = "BACKGROUND: The phase 2 BRIGHT AML 1003 trial evaluated efficacy and safety of glasdegib + low-dose cytarabine (LDAC) in patients with acute myeloid leukemia ineligible for intensive chemotherapy. The multicenter, open-label study randomized patients to receive glasdegib + LDAC (n = 78) or LDAC alone (n = 38). The rate of complete remission (CR) was 19.2% in the glasdegib + LDAC arm versus 2.6% in the LDAC arm (P = 0.015).METHODS: This post hoc analysis determines whether the clinical benefits of glasdegib are restricted to patients who achieve CR, or if they extend to those who do not achieve CR.RESULTS: In patients who did not achieve CR, the addition of glasdegib to LDAC improved overall survival (OS) versus LDAC alone (hazard ratio = 0.63 [95% confidence interval, 0.41-0.98]; P = 0.0182; median OS, 5.0 vs 4.1 months). Additionally, more patients receiving glasdegib + LDAC achieved durable recovery of absolute neutrophil count (≥ 1000/μl, 45.6% vs 35.5%), hemoglobin (≥ 9 g/dl, 54.4% vs 38.7%), and platelets (≥ 100,000/μl, 29.8% vs 9.7%). Transfusion independence was achieved by 15.0% and 2.9% of patients receiving glasdegib + LDAC and LDAC alone, respectively.CONCLUSIONS: Collectively, these data suggest that there are clinical benefits with glasdegib in the absence of CR.TRIAL REGISTRATION: ClinicalTrials.gov NCT01546038 (March 7, 2012).",
author = "Cortes, {Jorge E} and Heidel, {Florian H} and Walter Fiedler and Smith, {B Douglas} and Tadeusz Robak and Pau Montesinos and Anna Candoni and Brian Leber and Sekeres, {Mikkael A} and Pollyea, {Daniel A} and Roxanne Ferdinand and Ma, {Weidong Wendy} and Thomas O'Brien and Ashleigh O'Connell and Geoffrey Chan and Michael Heuser",
year = "2020",
month = jul,
day = "14",
doi = "10.1186/s13045-020-00929-8",
language = "English",
volume = "13",
pages = "92",
journal = "J HEMATOL ONCOL",
issn = "1756-8722",
publisher = "BioMed Central Ltd.",
number = "1",

}

RIS

TY - JOUR

T1 - Survival outcomes and clinical benefit in patients with acute myeloid leukemia treated with glasdegib and low-dose cytarabine according to response to therapy

AU - Cortes, Jorge E

AU - Heidel, Florian H

AU - Fiedler, Walter

AU - Smith, B Douglas

AU - Robak, Tadeusz

AU - Montesinos, Pau

AU - Candoni, Anna

AU - Leber, Brian

AU - Sekeres, Mikkael A

AU - Pollyea, Daniel A

AU - Ferdinand, Roxanne

AU - Ma, Weidong Wendy

AU - O'Brien, Thomas

AU - O'Connell, Ashleigh

AU - Chan, Geoffrey

AU - Heuser, Michael

PY - 2020/7/14

Y1 - 2020/7/14

N2 - BACKGROUND: The phase 2 BRIGHT AML 1003 trial evaluated efficacy and safety of glasdegib + low-dose cytarabine (LDAC) in patients with acute myeloid leukemia ineligible for intensive chemotherapy. The multicenter, open-label study randomized patients to receive glasdegib + LDAC (n = 78) or LDAC alone (n = 38). The rate of complete remission (CR) was 19.2% in the glasdegib + LDAC arm versus 2.6% in the LDAC arm (P = 0.015).METHODS: This post hoc analysis determines whether the clinical benefits of glasdegib are restricted to patients who achieve CR, or if they extend to those who do not achieve CR.RESULTS: In patients who did not achieve CR, the addition of glasdegib to LDAC improved overall survival (OS) versus LDAC alone (hazard ratio = 0.63 [95% confidence interval, 0.41-0.98]; P = 0.0182; median OS, 5.0 vs 4.1 months). Additionally, more patients receiving glasdegib + LDAC achieved durable recovery of absolute neutrophil count (≥ 1000/μl, 45.6% vs 35.5%), hemoglobin (≥ 9 g/dl, 54.4% vs 38.7%), and platelets (≥ 100,000/μl, 29.8% vs 9.7%). Transfusion independence was achieved by 15.0% and 2.9% of patients receiving glasdegib + LDAC and LDAC alone, respectively.CONCLUSIONS: Collectively, these data suggest that there are clinical benefits with glasdegib in the absence of CR.TRIAL REGISTRATION: ClinicalTrials.gov NCT01546038 (March 7, 2012).

AB - BACKGROUND: The phase 2 BRIGHT AML 1003 trial evaluated efficacy and safety of glasdegib + low-dose cytarabine (LDAC) in patients with acute myeloid leukemia ineligible for intensive chemotherapy. The multicenter, open-label study randomized patients to receive glasdegib + LDAC (n = 78) or LDAC alone (n = 38). The rate of complete remission (CR) was 19.2% in the glasdegib + LDAC arm versus 2.6% in the LDAC arm (P = 0.015).METHODS: This post hoc analysis determines whether the clinical benefits of glasdegib are restricted to patients who achieve CR, or if they extend to those who do not achieve CR.RESULTS: In patients who did not achieve CR, the addition of glasdegib to LDAC improved overall survival (OS) versus LDAC alone (hazard ratio = 0.63 [95% confidence interval, 0.41-0.98]; P = 0.0182; median OS, 5.0 vs 4.1 months). Additionally, more patients receiving glasdegib + LDAC achieved durable recovery of absolute neutrophil count (≥ 1000/μl, 45.6% vs 35.5%), hemoglobin (≥ 9 g/dl, 54.4% vs 38.7%), and platelets (≥ 100,000/μl, 29.8% vs 9.7%). Transfusion independence was achieved by 15.0% and 2.9% of patients receiving glasdegib + LDAC and LDAC alone, respectively.CONCLUSIONS: Collectively, these data suggest that there are clinical benefits with glasdegib in the absence of CR.TRIAL REGISTRATION: ClinicalTrials.gov NCT01546038 (March 7, 2012).

U2 - 10.1186/s13045-020-00929-8

DO - 10.1186/s13045-020-00929-8

M3 - SCORING: Journal article

C2 - 32664995

VL - 13

SP - 92

JO - J HEMATOL ONCOL

JF - J HEMATOL ONCOL

SN - 1756-8722

IS - 1

ER -